Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.60), $0.09 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $48.8 million versus the consensus estimate of $49.81 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.